Entera Bio (Nasdaq:ENTX) - Aandelenkoers, Nieuws & Analyse

ENTX Overzicht aandelen

ENTX fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 2.3% per jaar gegroeid

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 89.7% per jaar dalen.

Heeft een omzet van minder dan 1 miljoen USD ( $57K )

Heeft geen betekenisvolle marktkapitalisatie ( $65M )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 2 meer risico's

Entera Bio Ltd. Concurrenten

RAPT Therapeutics

NasdaqGM:RAPT

US$77.8m

vTv Therapeutics

NasdaqCM:VTVT

US$42.2m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

SAB Biotherapeutics

NasdaqCM:SABS

US$35.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Entera Bio
Historische aandelenkoersen
Huidige aandelenkoers	US$1.80
52 Week Hoogtepunt	US$3.35
52 Week Laag	US$0.52
Bèta	1.58
11 maand verandering	-3.74%
3 maanden verandering	21.62%
1 Jaar Verandering	193.69%
33 jaar verandering	-56.10%
5 jaar verandering	-25.31%
Verandering sinds IPO	-71.34%

Recent nieuws en updates

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Jul 12

Recent updates

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Jul 12

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Oct 06

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jun 19

Entera Bio secures European patent for oral PTH formulations

Jun 17

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Mar 20

Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Dec 05

Entera Bio EPS misses by $0.22

Nov 19

Rendement voor aandeelhouders

	ENTX	US Biotechs	US Markt
7D	-4.3%	-0.4%	-1.2%
1Y	193.7%	20.1%	30.6%

Rendement versus industrie: ENTX overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 20.1 % opleverde.

Rendement versus markt: ENTX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 30.6 %.

Prijsvolatiliteit

Is ENTX's price volatile compared to industry and market?
ENTX volatility
ENTX Average Weekly Movement	10.1%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van ENTX is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van ENTX is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	18	Miranda Toledano	www.enterabio.com

Entera Bio Ltd., een bedrijf in een klinische fase, richt zich op de ontwikkeling van orale peptide- of eiwitvervangingstherapieën voor onvervulde medische behoeften waarbij een orale tabletvorm het potentieel heeft om de zorgstandaard te veranderen. Het bedrijf maakt gebruik van zijn N-Tab, een technologie voor orale toediening, die is ontworpen om tegelijkertijd de peptide in het maagdarmkanaal te stabiliseren en de absorptie ervan in de bloedbaan te bevorderen. Zijn geavanceerde productkandidaat is EB613 (oraal PTH (1-34)), dat in Fase 3 ontwikkeling gaat als de eerste orale, osteoanabole (botopbouwende) tabletbehandeling voor éénmaal daags gebruik voor postmenopauzale vrouwen met een lage botmineraaldichtheid en osteoporose met een hoog risico.

Entera Bio Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Entera Bio zich tot de beurswaarde?
ENTX fundamentele statistieken
Marktkapitalisatie	US$65.38m
Inkomsten(TTM)	-US$8.54m
Inkomsten(TTM)	US$57.00k

1,147x

P/S-verhouding

-7.7x

Koers/Winstverhouding

Is ENTX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ENTX resultatenrekening (TTM)
Inkomsten	US$57.00k
Kosten van inkomsten	US$48.00k
Brutowinst	US$9.00k
Overige uitgaven	US$8.55m
Inkomsten	-US$8.54m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.23
Brutomarge	15.79%
Nettowinstmarge	-14,975.44%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ENTX op de lange termijn?

Bekijk historische prestaties en vergelijking

ENTX Overzicht aandelen

Beloningen

Risicoanalyse

Entera Bio Ltd. Concurrenten

NasdaqGM:RAPT

US$77.8m

NasdaqCM:VTVT

US$42.2m

NasdaqGS:FIXX

US$54.3m

NasdaqCM:SABS

US$35.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New minor risk - Share price stability

Entera Bio Ltd. Announces New Comparative Pharmacological Data for its Investigational Agent EB613 Vs. Forteo® Selected for Presentation at ASBMR

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Jul 31, 2024

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Recent updates

New minor risk - Share price stability

Entera Bio Ltd. Announces New Comparative Pharmacological Data for its Investigational Agent EB613 Vs. Forteo® Selected for Presentation at ASBMR

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Jul 31, 2024

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New minor risk - Shareholder dilution

Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Third quarter 2023 earnings released: US$0.083 loss per share (vs US$0.11 loss in 3Q 2022)

Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program

Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting

New minor risk - Share price stability

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Entera Bio Ltd., Annual General Meeting, Sep 13, 2023

First half 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1H 2022)

Entera Bio Ltd Adds Haya Taitel to its Board of Directors

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Consensus revenue estimates decrease by 97%, EPS upgraded

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)

Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

No longer forecast to breakeven

Entera Bio Ltd. Announces U.S. Food and Drug Administration Acceptance of Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Price target decreased by 11% to US$6.00

Entera Bio Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates increase by 59%

Price target increased to US$9.50

Insufficient new directors

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio Ltd. Announces Fda Agreement for A Single Phase 3 Clinical Trial to Support an NDA for Eb613 for the Treatment of Osteoporosis

Entera Bio Ltd. Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Price target increased to US$7.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Sep 07, 2022

Entera Bio Ltd. Announces Executive Changes

Insufficient new directors

Entera Bio Ltd. Announces Departure of Dr. Phillip Schwartz, President of Research & Development to Pursue Outside Opportunities

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Entera Bio Ltd. Announces Appointment of Miranda Toledano as Chief Business Officer and Head of Corporate Strategy

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$6.75

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Entera Bio Ltd. Provides Earnings Guidance for the Year Ending December 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Entera Bio Ltd. to Report Fiscal Year 2021 Results on Mar 08, 2022